摘要
目的研究人参皂苷Rg_3对小鼠非小细胞肺癌Lewis细胞(LLC)中免疫检查点程序性死亡分子1配体(PD-L1)的调节作用及其作用机制。方法通过MTT法及细胞长时程动态监测法观察人参皂苷Rg_3对LLC增殖的影响;20 ng/mLγ干扰素(IFN-γ)处理LLC制备PD-L1高表达体外模型,采用人参皂苷Rg_3进行干预,流式细胞术及免疫荧光检测人参皂苷Rg_3对PD-L1表达的影响;采用Western blotting法验证人参皂苷Rg_3对PI3K/蛋白激酶B(Akt)/哺乳动物雷帕霉素靶蛋白(m TOR)通路相关蛋白表达的影响。结果人参皂苷Rg_3 16、32、64、128μmol/L能够显著抑制LLC增殖(P<0.01)及减少IFN-γ诱导的PD-L1表达(P<0.05);人参皂苷Rg_3 32、64μmol/L能够降低PI3K、m TOR蛋白的表达水平(P<0.01);人参皂苷Rg_3 16、32、64μmol/L能够抑制Akt蛋白的磷酸化(P<0.05)。结论人参皂苷Rg_3能够显著抑制LLC中PD-L1表达,通过抑制PI3K/Akt/m TOR通路,阻断PD-L1介导的肿瘤细胞免疫逃逸,增强T细胞的免疫应答作用,抑制LLC生长。
Objective To investigate the effect of ginsenoside Rg3 on immune checkpoint PD-L1 in Lewis cells(LLC) and to explore the related mechanism. Methods The effects of ginsenoside Rg3 on the proliferation of LLC were observed by MTT assay and cell long-term dynamic monitoring. LLC cells treated with 20 ng/m L IFN-γ were used to construct experimental model with high expression of PD-L1 in vitro. The effect of ginsenoside Rg3 on expression of PD-L1 was detected by flow cytometry and immunofluorescence. The effect of ginsenoside Rg3 on the protein expression of PI3 K/Akt/mTOR pathway was verified by Western blotting. Results Ginsenoside Rg3 at 16, 32, 64, and 128 μmol/L significantly inhibited the proliferation of LLC(P < 0.01) and reduced the expression of PD-L1 induced by IFN-γ(P < 0.05). Ginsenoside Rg3 at 32 and 64 μmol/L significantly decreased the protein expression of PI3 K and mTOR(P < 0.01), and ginsenoside Rg3 at 16, 32, and 64 μmol/L significantly inhibited the phosphorylation of Akt proteins(P < 0.05). Conclusion Ginsenoside Rg3 significantly inhibited the expression of PD-L1 in LLC cells by inhibiting PI3 K/Akt/mTOR pathway. Ginsenoside Rg3 blocked the tumor cells escaping immune response by PD-L1 over-expression, enhanced the immune response of T cells, and inhibited the growth of non-small cell lung cancer cells.
作者
王蔚
王旭
余苏云
黄帅
丁语石
陈文星
王爱云
陆茵
WANG Wei;WANG Xu;YU Su-yun;HUANG Shuai;DING Yu-shi;CHEN Wen-xing;WANG Ai-yun;LU Yin(Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica,School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China;Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor,Nanjing University of Chinese Medicine,Nanjing 210023,China)
出处
《中草药》
CAS
CSCD
北大核心
2019年第1期166-171,共6页
Chinese Traditional and Herbal Drugs
基金
国家自然科学基金资助项目(81403260)
国家自然科学基金资助项目(81673725)
国家自然科学基金资助项目(81573859)
国家自然科学基金资助项目(81673648)
国家自然科学基金资助项目(81703765)
江苏省研究生创新基金项目(KYCX18_1584)
江苏省研究生创新基金项目(KYCX18_1616)
江苏省研究生创新基金项目(KYCX17_1315)
江苏省自然科学基金项目(BK20151567)
江苏高校品牌专业建设工程资助项目(TAPP-PPZY2015A070)
江苏高校中药学优势学科建设工程资助项目(PAPD)[苏政办发(2014)37号文]
江苏省中医药领军人才项目(SLJ0229)